DRAK

DRAK2 (death-associated protein kinase-related apoptosis-inducing kinase 2) is a serine/threonine kinase belonging to the DAPK family, exerting key roles in apoptosis regulation and T lymphocyte activation^[1][2]. Mechanistically, DRAK2 modulates RNA splicing via SRSF6 and influences β-cell apoptosis in type I diabetes, integrating upstream signaling with cellular stress responses^[1]. In disease models, DRAK2 contributes to colorectal cancer progression, chronic lymphocytic leukemia, acute myeloid leukemia, and exacerbation of alcoholic fatty liver disease, highlighting its context-dependent pathogenic relevance^[1]. Compared with related isoforms DRAK1 and DAPK1-3, DRAK2 demonstrates distinct tissue-specific expression and selective engagement in immune and metabolic pathways, underpinning isoform-specific functional outcomes^[1][2]. Small-molecule inhibitors targeting DRAK2 have been developed to probe these biological pathways and offer potential therapeutic strategies, though clinical translation remains limited due to selectivity challenges^[1][2]. Functionally, DRAK2’s modulation of apoptosis and immune signaling provides a robust experimental model for dissecting kinase-mediated regulation in both cancer and metabolic disease contexts^[1][2]. Therefore, DRAK2 represents a critical node linking apoptosis, kinase signaling, and disease pathophysiology with isoform-specific distinctions exploitable in research and potential pharmacological interventions^[1][2].